207 related articles for article (PubMed ID: 22209268)
1. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?
Brugaletta S; Radu MD; Garcia-Garcia HM; Heo JH; Farooq V; Girasis C; van Geuns RJ; Thuesen L; McClean D; Chevalier B; Windecker S; Koolen J; Rapoza R; Miquel-Hebert K; Ormiston J; Serruys PW
Atherosclerosis; 2012 Mar; 221(1):106-12. PubMed ID: 22209268
[TBL] [Abstract][Full Text] [Related]
2. Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.
Gutiérrez-Chico JL; Gijsen F; Regar E; Wentzel J; de Bruyne B; Thuesen L; Ormiston J; McClean DR; Windecker S; Chevalier B; Dudek D; Whitbourn R; Brugaletta S; Onuma Y; Serruys PW
JACC Cardiovasc Interv; 2012 Apr; 5(4):428-35. PubMed ID: 22516401
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
[TBL] [Abstract][Full Text] [Related]
4. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
5. Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data.
Bourantas CV; Serruys PW; Nakatani S; Zhang YJ; Farooq V; Diletti R; Ligthart J; Sheehy A; van Geuns RJ; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Rapoza R; Veldhof S; Onuma Y; Garcia-Garcia HM
EuroIntervention; 2015 Nov; 11(7):746-56. PubMed ID: 25308301
[TBL] [Abstract][Full Text] [Related]
6. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
7. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
Zhang YJ; Iqbal J; Nakatani S; Bourantas CV; Campos CM; Ishibashi Y; Cho YK; Veldhof S; Wang J; Onuma Y; Garcia-Garcia HM; Dudek D; van Geuns RJ; Serruys PW;
JACC Cardiovasc Interv; 2014 Dec; 7(12):1361-9. PubMed ID: 25457053
[TBL] [Abstract][Full Text] [Related]
8. Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial.
Bourantas CV; Farooq V; Zhang Y; Muramatsu T; Gogas BD; Thuesen L; McClean D; Chevalier B; Windecker S; Koolen J; Ormiston J; Whitbourn R; Dorange C; Rapoza R; Onuma Y; Garcia-Garcia HM; Serruys PW
EuroIntervention; 2015 Mar; 10(11):1299-306. PubMed ID: 24769420
[TBL] [Abstract][Full Text] [Related]
9. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
10. Neointimal response to everolimus-eluting bioresorbable scaffolds implanted at bifurcating coronary segments: insights from optical coherence tomography.
Sato T; Jose J; El-Mawardy M; Sulimov DS; Tölg R; Richardt G; Abdel-Wahab M
Int J Cardiovasc Imaging; 2017 Feb; 33(2):169-175. PubMed ID: 27757563
[TBL] [Abstract][Full Text] [Related]
11. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
[TBL] [Abstract][Full Text] [Related]
12. A 12-month angiographic and optical coherence tomography follow-up after bioresorbable vascular scaffold implantation in patients with ST-segment elevation myocardial infarction.
Kochman J; Tomaniak M; Kołtowski Ł; Jąkała J; Proniewska K; Legutko J; Roleder T; Pietrasik A; Rdzanek A; Kochman W; Brugaletta S; Kaluza GL
Catheter Cardiovasc Interv; 2015 Oct; 86(4):E180-9. PubMed ID: 26015294
[TBL] [Abstract][Full Text] [Related]
13. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies.
Gogas BD; Radu M; Onuma Y; Perkins L; Powers JC; Gomez-Lara J; Farooq V; Garcia-Garcia HM; Diletti R; Rapoza R; Virmani R; Serruys PW
Int J Cardiovasc Imaging; 2012 Mar; 28(3):499-511. PubMed ID: 21503708
[TBL] [Abstract][Full Text] [Related]
14. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography study.
Bourantas CV; Papafaklis MI; Kotsia A; Farooq V; Muramatsu T; Gomez-Lara J; Zhang YJ; Iqbal J; Kalatzis FG; Naka KK; Fotiadis DI; Dorange C; Wang J; Rapoza R; Garcia-Garcia HM; Onuma Y; Michalis LK; Serruys PW
JACC Cardiovasc Interv; 2014 Mar; 7(3):315-24. PubMed ID: 24529931
[TBL] [Abstract][Full Text] [Related]
15. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
[TBL] [Abstract][Full Text] [Related]
16. Two-week interval optical coherence tomography: imaging evidence on neointimal coverage completion after implantation of the Endeavor zotarolimus-eluting stent.
Nishinari M; Shimohama T; Tojo T; Shiono T; Shinagawa H; Kameda R; Aoyama N; Izumi T
Catheter Cardiovasc Interv; 2013 Dec; 82(7):E871-8. PubMed ID: 23873677
[TBL] [Abstract][Full Text] [Related]
17. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and qualitative changes in DES-related neointimal tissue based on serial OCT.
Kim JS; Hong MK; Shin DH; Kim BK; Ko YG; Choi D; Jang Y
JACC Cardiovasc Imaging; 2012 Nov; 5(11):1147-55. PubMed ID: 23153915
[TBL] [Abstract][Full Text] [Related]
19. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance.
Mattesini A; Secco GG; Dall'Ara G; Ghione M; Rama-Merchan JC; Lupi A; Viceconte N; Lindsay AC; De Silva R; Foin N; Naganuma T; Valente S; Colombo A; Di Mario C
JACC Cardiovasc Interv; 2014 Jul; 7(7):741-50. PubMed ID: 25060016
[TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial.
Okamura T; Garg S; Gutiérrez-Chico JL; Shin ES; Onuma Y; García-García HM; Rapoza RJ; Sudhir K; Regar E; Serruys PW
EuroIntervention; 2010 Apr; 5(8):932-8. PubMed ID: 20542778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
